Medline is growing quickly, but heavy debt and margin pressure keep the stock in disciplined Buy territory. The report sees solid medium-term upside, with fair value above the recent trading price.
Medline Inc. (MDLN) offers a credible medium-term growth story, but its elevated debt and recent margin pressure justify a disciplined Buy rather than an aggressive position. The company generated $28.4B of 2025 revenue, $3.5B of adjusted EBITDA and $1.2B of net income. In Q1 2026, revenue reached $7.4B, up 10.7% year over year, while management raised full-year organic sales growth guidance to 8.5% to 9.5%.
The May 21, 2026 closing sales price of $37.10 sits below the analyst price target of $50.65. A fair value estimate of $45.00 reflects Medline's strong sales momentum, broad product portfolio and customer retention, while applying a discount for $12.6B of debt, 3.1x net leverage and the profit hit from tariffs.
The investment case depends on growth converting into cash flow and debt reduction. Q1 2026 adjusted EBITDA fell 10.6% to $776M despite the sales increase, and quarterly net income in the financial statements fell to $129M from $322M a year earlier. Medline has a strong commercial engine, but the balance sheet leaves less room for operational mistakes than the company's sales growth alone might imply.
Founded in 1966 and headquartered in Northfield, Illinois, Medline manufactures and distributes medical-surgical products across hospitals, surgery centers, physician offices, post-acute facilities and nursing homes. The company employs approximately 45,000 people and trades on Nasdaq under the ticker MDLN after its IPO on December 17, 2025.
Medline operates through two segments: Medline Brand and Supply Chain Solutions. The business combines manufacturing, procurement, distribution and logistics rather than relying on a single point in the healthcare supply chain. Its catalog includes roughly 335,000 products, spanning surgical kits, gloves, protective apparel, wound care, incontinence, laboratory supplies, diagnostics and other routine clinical products.
The scale is material. Medline reported $28.4B of 2025 revenue, and the current trailing revenue figure is $29.1B. The company also reported $3.0B of EBITDA and $2.2B of free cash flow on the current trailing measure. Those figures establish Medline as a large healthcare infrastructure business rather than a narrow medical-device manufacturer.
In 2025, Medline Brand generated $13.7B of sales and $3.3B of segment EBITDA. Supply Chain Solutions generated $14.7B of sales and $0.8B of segment EBITDA. The two businesses therefore play different roles: Medline Brand carries the higher reported profitability, while Supply Chain Solutions expands the customer relationship through distribution and logistics.
The Q1 2026 results showed the contrast clearly. Medline Brand sales rose 7.4% to $3.5B, while segment adjusted EBITDA fell 7.8% to $765M. Surgical Solutions sales rose 7.4%, supported by operating-room and kitting volumes. Front Line Care grew 6.0%, while Lab and Diagnostics was approximately flat because core growth was offset by lower respiratory volumes during a milder illness season.
Supply Chain Solutions was the faster-growing segment in Q1. Sales increased 15.0% to $3.9B, driven by Prime Vendor sales, new customer implementations and existing-customer growth. Segment adjusted EBITDA increased 2.7% to $182M, but customer mix and higher operating expenses limited the earnings conversion. That gap matters: revenue growth is valuable only when new accounts produce acceptable margins after implementation costs.
Medline's Prime Vendor agreements had an approximate average mix of 65% Supply Chain Solutions and 35% Medline Brand at the end of 2025. Increasing the Medline Brand share inside those accounts provides a specific path toward better economics because the company controls the branded product portfolio as well as the distribution relationship.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Medline's flagship commercial offering is best understood as an integrated surgical and supply-chain package rather than a single product. Surgical Solutions includes procedure trays, surgical drapes and gowns, personal protective equipment, sterile wraps, instruments, surgeon's gloves, procedure kits and orthopedic implants. These products sit close to operating-room workflows, where product availability and standardized kits can influence staff time and procedure execution.
Q1 2026 Surgical Solutions growth of 7.4% was driven by operating-room and kitting products. The result gives the surgical portfolio a concrete role in the growth thesis, especially as healthcare providers seek fewer vendors and more standardized purchasing. Medline's product breadth allows a customer to source procedure-specific items alongside routine front-line supplies.
Front Line Care provides the recurring-use base of the portfolio. Its products include wound care, exam gloves, skin care, incontinence, environmental cleaning, textiles, hand sanitizer, durable medical equipment, patient plastics and infection-control products. Lab and Diagnostics adds point-of-care testing, analyzers, consumables, vital-sign monitors and pathology products. This breadth reduces dependence on one clinical category, although it also exposes Medline to broad input-cost and procurement pressure.
Medline's strongest advantage is the combination of manufacturing and distribution. The company says it manufactures approximately one-third of Medline Brand products, while its distribution network and commercial teams provide direct access to healthcare customers. That structure gives MDLN more control over product availability, pricing, service levels and customer implementation than a pure distributor or a manufacturer dependent on third-party channels.
The operating footprint reinforces that advantage. Medline has 70 global distribution centers, 24 North American manufacturing sites and more than 2,100 MedTrans trucks. It reports 95% next-day delivery to U.S. customers and more than 98% Prime Vendor customer retention over the last five years. Those are tangible service metrics, not merely corporate language.
Innovation is focused on logistics and workflow. Medline is piloting Symbotic's AI-powered robotic platform for bulk-item picking, storage and retrieval. It launched Pick Pack Pro for health plan customers and expanded the Mpower pilot, which has produced early efficiency and inventory-planning benefits. These programs matter because supply-chain automation can strengthen customer economics while reducing the labor intensity of distribution.
The company is directing 2026 capital expenditures toward distribution-center automation and kitting facilities. Planned projects include capacity expansion at the Mexico kitting facility and two additional distribution centers in California and Texas. Growth investment is therefore tied to specific assets rather than an abstract technology narrative.
Medline's supply chain is both a competitive asset and a source of financial risk. The company operates its own distribution and transportation network, but it also imports products and materials. The 2025 annual report states that 5.0% of cost of goods sold came from China. That exposure creates sensitivity to tariffs, trade restrictions, foreign logistics and sourcing delays.
Tariffs have already reached the income statement. Medline reported an approximately $290M adverse impact to income before taxes from tariffs and tariff developments in 2025. The annual report estimated an additional approximately $200M adverse impact for fiscal 2026 based on tariffs in effect at December 31, 2025. Q1 2026 profitability also reflected higher cost of goods sold, including tariffs.
The cash-flow record shows that the network can generate substantial liquidity. 2025 operating cash flow was $1.7B, capital expenditures were $447M and free cash flow was $1.3B. Q1 2026 free cash flow was $316M after $96M of capital expenditures. The planned 2026 net capital expenditure budget of approximately $500M will support capacity and automation, but it also competes with debt paydown for available cash.
Medline estimates the global healthcare supplies opportunity at approximately $375B, including $175B in the U.S. and $200B internationally. Against that backdrop, the company's $28.4B of 2025 revenue represents a large operating base inside a market that still has room for share gains and geographic expansion.
Demand is supported by specific care-delivery changes. Hospitals accounted for 67.6% of the medical supplies market in 2025, while home-care settings were identified as the fastest-growing end market at an 8.98% projected CAGR through 2031. Ambulatory surgery centers perform more than 25 million U.S. procedures annually, with annual growth of 3% to 4%. These trends favor standardized, procedure-specific and portable medical supplies.
The market also faces cost pressure. McKinsey expects continued margin pressure across healthcare in 2026, while Medline's own Q1 results showed how that pressure can pass through to suppliers. The combination of growing utilization and tighter provider budgets favors vendors that can demonstrate lower total cost, reliable delivery and measurable inventory efficiency.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Medline serves hospitals, surgery centers, physician offices, post-acute facilities and nursing homes. Its customer proposition is strongest where a provider wants a single partner for products, ordering, logistics and inventory management. The Prime Vendor model embeds Medline into purchasing and replenishment workflows rather than treating the company as a supplier of isolated products.
Customer concentration is a material risk. Approximately $19.7B, or 69% of consolidated 2025 sales, came from member hospitals under contracts with Medline's three largest group purchasing organizations: Vizient, HealthTrust and Premier. Those sales represented 74% of U.S. revenue. Contract renewals, pricing terms and GPO relationships therefore have an outsized effect on results.
The customer engine is still expanding. Medline reported $2.4B of total new customer signings in 2025, and Q1 2026 included new customer implementations, competitor displacements and a first Prime Vendor customer in Canada through Mohawk Medbuy Corporation. The more important commercial metric is conversion: Q1 Supply Chain Solutions revenue grew 15.0%, while segment EBITDA grew only 2.7% because implementation mix and operating expenses absorbed much of the gain.
Medline competes with both medical-product manufacturers and distributors. Named distribution competitors include McKesson (MCK), Cardinal Health (CAH), Owens & Minor (OMI) and Henry Schein (HSIC). Becton Dickinson (BDX) and Baxter (BAX) overlap with Medline in selected consumable and hospital-product categories.
Medline's stated differentiation is its hybrid model. McKesson and Cardinal Health have much broader pharmaceutical distribution exposure, while Medline is concentrated in medical-surgical products and supply-chain solutions. Owens & Minor and Henry Schein provide distribution overlap, but Medline combines distribution with a large branded product portfolio and a manufacturing base.
Scale strengthens the proposition. Medline describes itself as the largest provider of medical-surgical products and supply-chain solutions serving all points of care, measured by total net sales among companies that both manufacture and distribute med-surg products. Its 335,000-product catalog, 70 distribution centers and more than 98% Prime Vendor retention give the company practical advantages in procurement, logistics and account integration.
The demand backdrop is relatively defensive. Medline cites CMS expectations for national health expenditures to grow 5.6% annually from 2023 through 2032. Aging populations and chronic disease also support demand for wound care, incontinence, infusion, respiratory and other recurring-use products.
Trade policy is the dominant macro risk in the current data. The 2025 tariff impact of approximately $290M, the estimated fiscal 2026 impact of approximately $200M and the 5.0% China share of cost of goods sold show that geopolitical decisions can materially affect earnings even when revenue growth remains strong.
Regulation adds a second external risk. Medline's products are subject to FDA and other regulatory requirements, including product-quality, recall and liability exposure. The business benefits from healthcare demand that is less discretionary than many industries, but it operates in a sector where a quality or compliance issue can affect distribution and customer trust.
With $12.6B of debt and 3.1x net leverage, Medline’s balance sheet leaves less room for execution missteps even as cash generation improves.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q1 2026 revenue rose 10.7% to $7.4B, but adjusted EBITDA still fell 10.6% to $776M and net income dropped to $129M.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted full-year organic sales growth guidance to 8.5% to 9.5%, signaling continued top-line momentum into 2026.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At $37.10, the stock trades below the $50.65 analyst target and below the report’s $45 fair value estimate.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s $45 fair value sits above the May 21, 2026 close of $37.10, leaving room for upside if margins stabilize.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Medline is a high-quality operating platform with a less comfortable financial structure. Its $28.4B of annual sales, 335,000-product catalog, 70 distribution centers and 98% or better Prime Vendor retention create a durable commercial base. Q1 2026 revenue growth of 10.7% and the raised organic sales outlook show that customer demand and implementation activity remain strong.
CEO Jim Boyle's description fits the sales performance, but the income statement adds an important qualification. Tariffs, higher operating expenses and IPO-related compensation reduced Q1 profitability, while the annual balance sheet carries $12.6B of debt. Investors are not buying a finished deleveraging story; they are buying a scale leader with the cash generation and growth outlook to improve that story.
At the May 21 price of $37.10, the risk-reward profile supports a Buy for a moderate-risk, medium-term portfolio, with a fair value estimate of $45.00. The thesis strengthens if Medline converts Supply Chain Solutions growth into EBITDA, protects Medline Brand margins and uses free cash flow to reduce leverage. Until those outcomes become visible in reported results, disciplined exposure remains more sensible than enthusiasm without a balance-sheet check.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Medline Inc. (MDLN) falls sharply after reporting second-quarter 2026 results, with shares dropping nearly 15% in after-hours trading. The move reflects investor concern over margins, guidance, and whether strong sales growth can translate into better profits.
Medline is growing at scale with strong customer retention and a deep med-surg distribution network, but margin pressure and a rich valuation keep the stock from looking cheap.
Medline Inc. (MDLN) drops sharply after its Q1 2026 earnings report showed strong revenue growth but weaker profitability. Investors are reacting to margin compression from tariffs, higher operating costs, and IPO-related expenses, even as full-year sales guidance improved.